U.S. Branded Generics Market Size & Outlook, 2026-2033
Related Markets
U.S. branded generics market highlights
- The U.S. branded generics market generated a revenue of USD 47,567.0 million in 2025 and is expected to reach USD 71,824.2 million by 2033.
- The U.S. market is expected to grow at a CAGR of 5.4% from 2026 to 2033.
- In terms of segment, oral was the largest revenue generating route of administration in 2025.
- Parenteral is the most lucrative route of administration segment registering the fastest growth during the forecast period.
Branded generics market data book summary
| Market revenue in 2025 | USD 47,567.0 million |
| Market revenue in 2033 | USD 71,824.2 million |
| Growth rate | 5.4% (CAGR from 2026 to 2033) |
| Largest segment | Oral |
| Fastest growing segment | Parenteral |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Topical, Oral, Parenteral, Others Route of Administration |
| Key market players worldwide | Teva Pharmaceutical Industries Ltd, Lupin, Sanofi SA, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, GlaxoSmithKline, Pfizer Inc, Apotex Inc., Viatris Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 17.2% of the global branded generics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. branded generics market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 2,098.7 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Branded Generics Market Scope
Branded Generics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Apotex Inc. | View profile | 10001+ | Toronto, Ontario, Canada, North America | http://www.apotex.com |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| Viatris Inc | View profile | 38000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | https://www.viatris.com |
| Dr. Reddy’s Laboratories | View profile | 10001+ | Hyderabad, Andhra Pradesh, India, Asia | http://www.drreddys.com/ |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | http://www.sunpharma.com |
| Lupin | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | https://www.lupin.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
U.S. branded generics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.
Oral was the largest segment with a revenue share of 62.07% in 2025. Horizon Databook has segmented the U.S. branded generics market based on topical, oral, parenteral, others route of administration covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. branded generics market is anticipated to witness moderate growth over the forecast period, owing to increase in number of ANDA approvals and first-to-file benefits, such as Paragraph IV (PIV) certification. As per U.S. FDA, the number of ANDA approvals increased from 971 in 2018 to 1,171 in 2019.
In addition, 107 first generic products were approved, which may contribute to market growth due to increased profitability through 180 days of exclusivity period. There is high competition among generic manufacturers in the U.S.
According to FDA, generic competition leads to cost savings of 95% in the U.S. However, this competitive environment leads to shortage of generic medicines, as operational costs are high. The buyers in the U.S. are leveraging the strong competition between manufacturers and excess capacity in manufacturing and R&D.
Reasons to subscribe to U.S. branded generics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. branded generics market databook
-
Our clientele includes a mix of branded generics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. branded generics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. branded generics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. branded generics market size, by drug class, 2021-2033 (US$M)
U.S. Branded Generics Market Outlook Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
